"Reverse" carbocyclic fleximers: synthesis of a new class of adenosine deaminase inhibitors. 2013

Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
Department of Chemistry and Biochemistry, University of Maryland, Baltimore, Maryland 21250, USA.

A series of flexible carbocyclic pyrimidine nucleosides has been designed and synthesized. In contrast to previously reported "fleximers" from our laboratory, these analogues have the connectivity of the heterocyclic base system "reversed", where the pyrimidine ring is attached to the sugar moiety, rather than the five membered imidazole ring. As was previously seen with the ribose fleximers, their inherent flexibility should allow them to adjust to enzyme binding site mutations, as well as increase the affinity for atypical enzymes. Preliminary biological screening has revealed surprising inhibition of adenosine deaminase, despite their lack of resemblance to adenosine.

UI MeSH Term Description Entries
D011741 Pyrimidine Nucleosides Pyrimidines with a RIBOSE attached that can be phosphorylated to PYRIMIDINE NUCLEOTIDES. Nucleosides, Pyrimidine
D000241 Adenosine A nucleoside that is composed of ADENINE and D-RIBOSE. Adenosine or adenosine derivatives play many important biological roles in addition to being components of DNA and RNA. Adenosine itself is a neurotransmitter. Adenocard,Adenoscan
D000243 Adenosine Deaminase An enzyme that catalyzes the hydrolysis of ADENOSINE to INOSINE with the elimination of AMMONIA. Adenosine Aminohydrolase,Aminohydrolase, Adenosine,Deaminase, Adenosine
D001665 Binding Sites The parts of a macromolecule that directly participate in its specific combination with another molecule. Combining Site,Binding Site,Combining Sites,Site, Binding,Site, Combining,Sites, Binding,Sites, Combining
D058892 Adenosine Deaminase Inhibitors Drugs that inhibit ADENOSINE DEAMINASE activity. ADA Inhibitors,Deaminase Inhibitors, Adenosine,Inhibitors, ADA,Inhibitors, Adenosine Deaminase

Related Publications

Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
January 2008, Nucleic acids symposium series (2004),
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
April 1977, Journal of medicinal chemistry,
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
May 2002, The Journal of organic chemistry,
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
January 2008, Nucleic acids symposium series (2004),
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
January 1982, Pharmacology & therapeutics,
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
March 1967, Journal of medicinal chemistry,
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
July 1998, Bioorganic & medicinal chemistry letters,
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
November 1977, Biochemical pharmacology,
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
November 1978, Biochemical and biophysical research communications,
Sarah C Zimmermann, and Joshua M Sadler, and Peter I O'Daniel, and Nathaniel T Kim, and Katherine L Seley-Radtke
July 1999, Bioorganic & medicinal chemistry letters,
Copied contents to your clipboard!